Ellipses in-licenses first-in-class B7H3 antibody drug conjugate from China

Ellipses Pharma Limited (“Ellipses”), a clinical-stage oncology drug development company with a pipeline of innovative ...
Nature

Ellipses Pharma: maximizing KOL input to increase the success rate of oncology R&D

Key opinion leader (KOL) input is associated with a higher success rate in drug development. However, many oncology programs fail to effectively use this critical resource, resulting in poor decision ...
Nature

Ellipses Pharma—distilling cancer drug development to its essence

Ellipses Pharma has implemented a disruptive approach to cancer drug development that greatly accelerates the delivery of novel solutions for patients. With seven lead products and a growing pipeline ...
Slate

What the

Earlier this summer, Choire Sicha, the writer, editor, and co-founder of the Awl, came to an unpleasant realization. His emails, he noticed, had veered into the realm of the ridiculous. “Suddenly, one ...
Business Wire

Ellipses Pharma and SunRock Biopharma Enter Into a Licensing Agreement for a First-in-class Bifunctional HER3:TRAIL Fusion Protein

LONDON & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)--SunRock Biopharma S.L. (“SunRock”), a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat ...
Indiatimes

What is 'Boomer Ellipses' in texting: Why Gen Z finds them confusing

Generational differences in punctuation use highlighted by 'Boomer Ellipses' phenomenon. Gen Z puzzled by older generations' extensive ellipsis use. Understanding historical context key to improving ...